VIDEO: BCMA-targeted CAR T offers ‘attractive option’ for advanced multiple myeloma
In this video, Nikhil C. Munshi, MD, from Dana-Farber Cancer Institute, discussed initial results from the KarMMa trial of idecabtagene vicleucel, a BCMA-targeted CAR T-cell therapy, which he presented at ASCO20 Virtual Scientific Program.
In this phase 2 study, treatment resulted in demonstrated deep, durable responses in heavily pretreated patients with relapsed and refractory multiple myeloma.
“Idecabtagene vicleucel is a really important treatment in this patient population. Toxicity is manageable, so it’s an attractive option for people who have been exposed to the three classes of drug in the relapsed or refractory setting,” he said in the video.
Collapse
Munshi NC, et al. Abstract 8503. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.